Sign in

    Ali Mohammed

    Research Analyst at Leerink Partners

    Ali Mohammed serves as an analyst at Leerink Partners, specializing in healthcare sector coverage with a focus on biopharmaceutical companies. He is known for his research contributions on leading firms such as Amicus Therapeutics, Amylyx Pharmaceuticals, and AN2 Therapeutics, delivering actionable insights and supporting investment decisions in these areas. Since joining Leerink Partners, Ali has built his career in healthcare equity research, leveraging expertise gained from previous analyst roles at financial institutions and maintaining relevant professional certifications. He holds FINRA registration and satisfies securities licensing requirements essential for his research analyst position.

    Ali Mohammed's questions to Vir Biotechnology (VIR) leadership

    Ali Mohammed's questions to Vir Biotechnology (VIR) leadership • Q4 2024

    Question

    Ali Mohammed from Leerink Partners asked about the potential for moving Vir's T-cell engagers into earlier lines of therapy given strong early signals. He also inquired how the company's machine learning and antibody engineering capabilities are being applied to optimize T-cell engager design.

    Answer

    Dr. Mark Eisner, CMO, confirmed interest in moving into earlier lines of therapy, particularly for the PSMA program, with more details to come. He also explained that Vir's dAIsY machine learning platform is being used to rapidly identify and optimize binders for the next generation of T-cell engagers. CEO Dr. Marianne De Backer added that their protein engineering platform uses a combination of internal and external models to quickly generate and test molecules with improved characteristics.

    Ask Fintool Equity Research AI